β‐catenin‐controlled tubular cell‐derived exosomes play a key role in fibroblast activation via the OPN‐CD44 axis
S Chen, M Zhang, J Li, J Huang, S Zhou… - Journal of …, 2022 - Wiley Online Library
Tubular injury and peripheral fibroblast activation are the hallmarks of chronic kidney
disease (CKD), suggesting intimate communication between the two types of cells …
disease (CKD), suggesting intimate communication between the two types of cells …
Responses to hypoxia: how fructose metabolism and hypoxia-inducible factor-1a pathways converge in health and disease
Abstract Purpose of Review Oxygen is critical for the high output of energy (adenosine
triphosphate) generated by oxidative phosphorylation in the mitochondria, and when oxygen …
triphosphate) generated by oxidative phosphorylation in the mitochondria, and when oxygen …
[HTML][HTML] Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
D Chen, Y Niu, F Liu, Y Yang, X Wang, P Li… - Frontiers in …, 2023 - frontiersin.org
Aim: We performed a systematic review and network meta-analysis evaluating the safety
and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among …
and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among …
Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta‐analysis including 13,146 …
H Chen, Q Cheng, J Wang, X Zhao… - Journal of clinical …, 2021 - Wiley Online Library
What is known and objective Previous studies based on small‐sample clinical data proved
that short‐term use of hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHD) inhibitors …
that short‐term use of hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHD) inhibitors …
[HTML][HTML] The hypoxia response pathway promotes PEP carboxykinase and gluconeogenesis in C. elegans
M Vora, SM Pyonteck, T Popovitchenko… - Nature …, 2022 - nature.com
Actively dividing cells, including some cancers, rely on aerobic glycolysis rather than
oxidative phosphorylation to generate energy, a phenomenon termed the Warburg effect …
oxidative phosphorylation to generate energy, a phenomenon termed the Warburg effect …
[HTML][HTML] Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic …
J Yang, J Xing, X Zhu, X Xie, L Wang… - Frontiers in …, 2023 - frontiersin.org
Objective To compare the effects of five hypoxia-inducible factor-prolyl hydroxylase domain
inhibitors (HIF-PHIs), two erythropoiesis-stimulating agents (ESAs), and placebo on iron …
inhibitors (HIF-PHIs), two erythropoiesis-stimulating agents (ESAs), and placebo on iron …
Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease
P Natale, SC Palmer, A Jaure… - Cochrane Database …, 2022 - cochranelibrary.com
Background Anaemia occurs in chronic kidney disease (CKD) and is more prevalent with
lower levels of kidney function. Anaemia in CKD is associated with death related to …
lower levels of kidney function. Anaemia in CKD is associated with death related to …
[HTML][HTML] Efficacy and safety of daprodustat vs rhEPO for anemia in patients with chronic kidney disease: a meta-analysis and trial sequential analysis
Z Fu, X Geng, K Chi, C Song, D Wu, C Liu… - Frontiers in …, 2022 - frontiersin.org
Introduction: Daprodustat, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-
PHI), its efficacy and safety remain unclear. Thus, we conducted this meta-analysis aiming at …
PHI), its efficacy and safety remain unclear. Thus, we conducted this meta-analysis aiming at …
[HTML][HTML] Efficacy and safety of vadadustat for anemia in patients with chronic kidney disease: a systematic review and meta-analysis
L Xiong, H Zhang, Y Guo, Y Song, Y Tao - Frontiers in Pharmacology, 2022 - frontiersin.org
Background: Vadadustat is a novel drug for treating anemia patients with chronic kidney
disease (CKD), but its effect and safety remain uncertain. This study aimed to summarize the …
disease (CKD), but its effect and safety remain uncertain. This study aimed to summarize the …
[HTML][HTML] Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta …
S Ren, X Yao, Y Li, Y Zhang, C Tong… - Frontiers in …, 2023 - frontiersin.org
The objective was to provide a comprehensive summary of existing evidence on the efficacy
and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) for the …
and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) for the …